AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21669162 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenicum Album LM 0/3 (verum)
Number of subjects: 28
Study 21669162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 19760283 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (280 mg)
Number of subjects: 60
Study 19760283 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (0 mg, placebo)
Number of subjects: 60
Study 17138082 — intervention group
Group type: COMPARATOR
Intervention: Landiolol 0 mg/kg (placebo)
Number of subjects: 0
Study 17138082 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol 0.1 mg/kg
Number of subjects: 0
Study 17138082 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol 0.2 mg/kg
Number of subjects: 0
Study 17138082 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol 0.3 mg/kg
Number of subjects: 0
Study 12921224 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg
Number of subjects: 30
Study 12921224 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg
Number of subjects: 30
Study 12921224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11266482 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical curettage
Number of subjects: 0
Study 11266482 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (HIV- patients as control)
Number of subjects: 0
Study 8940230 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PRP‐T/DTP vaccine
Number of subjects: 0
Study 8940230 — intervention group
Group type: COMPARATOR
Intervention: DTP vaccine only
Number of subjects: 0
Study 1416161 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN (glyceryl trinitrate) infusion at 0.5 micrograms.kg‐1.min‐1
Number of subjects: 53
Study 1416161 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 53
Study 1416161 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise increasing infusion of GTN
Number of subjects: 53
Study 2860284 — intervention group
Group type: EXPERIMENTAL
Intervention: Mérieux human diploid-cell-strain vaccine (HDCSV), 0.1 ml intradermally, at eight sites on day 0, at four sites on day 7, and at one site on days 28 and 91
Number of subjects: 155
Study 2860284 — intervention group
Group type: COMPARATOR
Intervention: Semple vaccine (SV)
Number of subjects: 155
Study 2860284 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine anti-rabies serum (EARS), 80 IU/kg on day 0
Number of subjects: 155
Study 2860284 — intervention group
Group type: EXPERIMENTAL
Intervention: Mérieux human diploid-cell-strain vaccine (HDCSV)
Number of subjects: 155
Study 29560777 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach Visits (OV)
Number of subjects: 100
Study 29560777 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 100
Study 26841216 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Advice
Number of subjects: 0
Study 26841216 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 0
Study 24650810 — intervention group
Group type: EXPERIMENTAL
Intervention: Take Home Naloxone (THN) kits distributed by trained paramedics
Number of subjects: 0
Study 24650810 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 0
Study 24650810 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up rates for patients consented and completed questionnaires (postal or telephone)
Number of subjects: 0
Study 24650810 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data about acceptability to patients and paramedics through interviews and focus groups
Number of subjects: 0
Study 22900984 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (GS)
Number of subjects: 45
Study 22900984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 19841161 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg bid alone
Number of subjects: 37
Study 19841161 — intervention group
Group type: COMPARATOR
Intervention: Lacosamide 200 mg bid with carbamazepine 200 mg bid
Number of subjects: 37
Study 19841161 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine 200 mg bid alone
Number of subjects: 37
Study 19841161 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine 200 mg bid with lacosamide 200 mg bid
Number of subjects: 37
Study 18543427 — intervention group
Group type: EXPERIMENTAL
Intervention: HyperHaes (combined hypertonic colloidal solution)
Number of subjects: 0
Study 15682287 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated CMR planning derived from gated scouts in free-breathing mode
Number of subjects: 10
Study 15682287 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated CMR planning derived from gated scouts in breath-holding mode
Number of subjects: 10
Study 15682287 — intervention group
Group type: COMPARATOR
Intervention: Manual CMR planning
Number of subjects: 10
Study 12173835 — intervention group
Group type: COMPARATOR
Intervention: Medtronic Octopus 3
Number of subjects: 100
Study 12173835 — intervention group
Group type: EXPERIMENTAL
Intervention: Genzyme Immobilizer
Number of subjects: 100
Study 10468701 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 12
Study 10468701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8713219 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate capsules, 220 mg three times a day
Number of subjects: 145
Study 8713219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 2105070 — intervention group
Group type: EXPERIMENTAL
Intervention: Target PaCO2 of 40 mmHg, measured at 37 degrees C
Number of subjects: 86
Study 2105070 — intervention group
Group type: EXPERIMENTAL
Intervention: Target PaCO2 corrected to patient's rectal temperature (mean 30.1, SD 1.9 degrees C)
Number of subjects: 86
Study 417372 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine at three dose levels
Number of subjects: 0
Study 417372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 417372 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0
Study 6805841 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine sulphate
Number of subjects: 50
Study 6805841 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 50
Study 30866922 — intervention group
Group type: EXPERIMENTAL
Intervention: Task trainer (Life/form®, Fort Atkinson WI)
Number of subjects: 150
Study 30866922 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional video
Number of subjects: 150
Study 30866922 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer practice
Number of subjects: 150
Study 30866922 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 150
Study 29465559 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group
Number of subjects: 130
Study 26858279 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 163
Study 26858279 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Continuous Training (ACT)
Number of subjects: 163
Study 26858279 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AIT and ACT
Number of subjects: 163
Study 24644095 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat 800/150 mg (FDC G003)
Number of subjects: 36
Study 24644095 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat 800/150 mg (FDC G004)
Number of subjects: 36
Study 24644095 — intervention group
Group type: COMPARATOR
Intervention: darunavir 800 mg and ritonavir 100 mg (single agents)
Number of subjects: 36
Study 24644095 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat (FDCs)
Number of subjects: 36
Study 22843789 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel therapy
Number of subjects: 855
Study 19597418 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (specific programme of exercise therapy twice a day throughout the entire hospitalization phase)
Number of subjects: 64
Study 19597418 — intervention group
Group type: COMPARATOR
Intervention: Standard mobilization programme (control group)
Number of subjects: 64
Study 17545373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccination at one fifth of a standard dose
Number of subjects: 112
Study 17545373 — intervention group
Group type: COMPARATOR
Intervention: Standard intramuscular vaccination
Number of subjects: 112
Study 16287454 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25- or 50-mg, titrated to 100-mg)
Number of subjects: 367
Study 16287454 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (10-mg, titrated to 20-mg)
Number of subjects: 367
Study 16287454 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 367
Study 12221405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Doppler tissue imaging (DTI) in BMD patients (A1: LVEF >= 55%, n=20; A2: LVEF < 55%, n=8)
Number of subjects: 66
Study 12221405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Doppler tissue imaging (DTI) in BMD patients (A1, A2) and carriers
Number of subjects: 66
Study 12221405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Doppler tissue imaging (DTI) in A2 and carriers
Number of subjects: 66
Study 12221405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Doppler tissue imaging (DTI) in A1, A2, and carriers
Number of subjects: 66
Study 12221405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Doppler tissue imaging (DTI)
Number of subjects: 66
Study 9620192 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion
Number of subjects: 25
Study 9620192 — intervention group
Group type: COMPARATOR
Intervention: Modified Madden protocol
Number of subjects: 25
Study 7632427 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical examination of adults with mental retardation
Number of subjects: 202
Study 7632427 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical disorders prevalence
Number of subjects: 202
Study 2653895 — intervention group
Group type: EXPERIMENTAL
Intervention: medium absorbant tampons
Number of subjects: 17
Study 2653895 — intervention group
Group type: EXPERIMENTAL
Intervention: super‐absorbant tampons
Number of subjects: 17
Study 2653895 — intervention group
Group type: COMPARATOR
Intervention: control (not specified)
Number of subjects: 17
Study 216094 — intervention group
Group type: EXPERIMENTAL
Intervention: letosteine (50 mg t.i.d.)
Number of subjects: 47
Study 216094 — intervention group
Group type: COMPARATOR
Intervention: S‐carboxy‐methyl‐cysteine (750 mg t.i.d.)
Number of subjects: 47
Study 31443727 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES + FES
Number of subjects: 48
Study 31443727 — intervention group
Group type: COMPARATOR
Intervention: Passive + FES (control)
Number of subjects: 48
Study 27473629 — intervention group
Group type: EXPERIMENTAL
Intervention: IV and perineural dexamethasone (1 ml of a 4 mg/ml dexamethasone solution)
Number of subjects: 40
Study 27473629 — intervention group
Group type: COMPARATOR
Intervention: IV dexamethasone alone (8 mg)
Number of subjects: 40
Study 26555779 — intervention group
Group type: EXPERIMENTAL
Intervention: ePAQ-PF (completed prior to visit)
Number of subjects: 284
Study 23600609 — intervention group
Group type: EXPERIMENTAL
Intervention: RMT at 55% of maximal inspiratory effort (EXP)
Number of subjects: 36
Study 23600609 — intervention group
Group type: COMPARATOR
Intervention: Control group at 10% of maximal inspiratory effort (CON)
Number of subjects: 36
Study 21690303 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug facts format
Number of subjects: 300
Study 21690303 — intervention group
Group type: COMPARATOR
Intervention: Traditional format
Number of subjects: 300
Study 21690303 — intervention group
Group type: EXPERIMENTAL
Intervention: Q&A format
Number of subjects: 300
Study 21690303 — intervention group
Group type: EXPERIMENTAL
Intervention: Highlights format
Number of subjects: 300
Study 19809205 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine controlled release (CR) 25 mg/day
Number of subjects: 26
Study 19809205 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day
Number of subjects: 26
Study 19809205 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine and Amlodipine
Number of subjects: 26
Study 17536870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bramitob (300mg nebulized dose)
Number of subjects: 11
Study 17536870 — intervention group
Group type: COMPARATOR
Intervention: Tobi (300mg nebulized dose)
Number of subjects: 11
Study 17536870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bramitob
Number of subjects: 11
Study 17536870 — intervention group
Group type: COMPARATOR
Intervention: Tobi
Number of subjects: 11
Study 17536870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bramitob and Tobi
Number of subjects: 11
Study 15297201 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based therapy
Number of subjects: 1759
Study 15297201 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination platinum/paclitaxel therapy
Number of subjects: 1759
Study 11030497 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI-MET group (those who met learning criterion)
Number of subjects: 28
Study 11030497 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI-NOT MET group (those who did not meet learning criterion)
Number of subjects: 28
Study 11030497 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 28
Study 11030497 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI-MET group
Number of subjects: 28
Study 11030497 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI-NOT MET group
Number of subjects: 28
Study 11030497 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (TBI-MET, TBI-NOT MET, HCs)
Number of subjects: 28
Study 9211021 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 7788
Study 9211021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7788
Study 8439017 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intravenous midazolam
Number of subjects: 48
Study 8439017 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 48
Study 3752417 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aerosol
Number of subjects: 0
Study 3752417 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 0
Study 31221679 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion threshold (transfuse if hemoglobin<7.5 g/dl)
Number of subjects: 4531
Study 31221679 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion threshold (transfuse if hemoglobin<9.5 g/dl in the operating room or ICU, or if hemoglobin<8.5 g/dl on the non-ICU ward)
Number of subjects: 4531
Study 31221679 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion threshold (transfuse if hemoglobin<7.5 g/dl) among patients with preoperative CKD
Number of subjects: 4531
Study 31221679 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion threshold (transfuse if hemoglobin<9.5 g/dl in the operating room or ICU, or if hemoglobin<8.5 g/dl on the non-ICU ward) among patients with preoperative CKD
Number of subjects: 4531
Study 27514371 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of solifenacin 5/10 mg + mirabegron 25/50 mg
Number of subjects: 1278
Study 27514371 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of solifenacin 10 mg + mirabegron 25 mg
Number of subjects: 1278
Study 27514371 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of solifenacin 5 mg + mirabegron 50 mg
Number of subjects: 1278
Study 27514371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1278
Study 27514371 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 1278
Study 25740286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy (administered intravenously every 2 weeks with pegfilgrastim support) with fluorouracil plus EC-P (FEC-P)
Number of subjects: 2091
Study 25740286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy (administered intravenously every 2 weeks with pegfilgrastim support) with EC-P
Number of subjects: 2091
Study 25740286 — intervention group
Group type: COMPARATOR
Intervention: Standard-interval chemotherapy (administered intravenously every 3 weeks) with FEC-P
Number of subjects: 2091
Study 25740286 — intervention group
Group type: COMPARATOR
Intervention: Standard-interval chemotherapy (administered intravenously every 3 weeks) with EC-P
Number of subjects: 2091
Study 25740286 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense chemotherapy (every 2 weeks)
Number of subjects: 2091
Study 25740286 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of fluorouracil to chemotherapy
Number of subjects: 2091
Study 23328090 — intervention group
Group type: EXPERIMENTAL
Intervention: lersivirine 500 mg once daily with tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 193
Study 23328090 — intervention group
Group type: EXPERIMENTAL
Intervention: lersivirine 750 mg once daily with tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 193
Study 23328090 — intervention group
Group type: COMPARATOR
Intervention: efavirenz 600 mg once daily with tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 193
Study 23328090 — intervention group
Group type: EXPERIMENTAL
Intervention: lersivirine 500 mg
Number of subjects: 193
Study 23328090 — intervention group
Group type: EXPERIMENTAL
Intervention: lersivirine 750 mg
Number of subjects: 193
Study 23328090 — intervention group
Group type: COMPARATOR
Intervention: efavirenz
Number of subjects: 193
Study 23328090 — intervention group
Group type: EXPERIMENTAL
Intervention: lersivirine
Number of subjects: 193
Study 22268268 — intervention group
Group type: EXPERIMENTAL
Intervention: Speculum retention technique
Number of subjects: 100
Study 22268268 — intervention group
Group type: COMPARATOR
Intervention: Conventional transfer technique
Number of subjects: 100
Study 19057955 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colon resection (LCR)
Number of subjects: 391
Study 19057955 — intervention group
Group type: EXPERIMENTAL
Intervention: Included patients (group 1)
Number of subjects: 391
Study 19057955 — intervention group
Group type: COMPARATOR
Intervention: Nonincluded patients (group 4)
Number of subjects: 391
Study 16435117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed pharmaceutical budgets
Number of subjects: 0
Study 16435117 — intervention group
Group type: COMPARATOR
Intervention: Open-ended budgets
Number of subjects: 0
Study 12742982 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-7 levels in patients with unstable angina
Number of subjects: 80
Study 12742982 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-7 levels in patients with stable angina
Number of subjects: 80
Study 12742982 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-7 expression in peripheral blood mononuclear cells
Number of subjects: 80
Study 12742982 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (160 mg qd for 7 days)
Number of subjects: 80
Study 10823263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (adequate LDL-C reduction)
Number of subjects: 57
Study 10823263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (inadequate LDL-C reduction)
Number of subjects: 57
Study 10823263 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with LDL-C reduction)
Number of subjects: 57
Study 10823263 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without LDL-C reduction)
Number of subjects: 57
Study 8888744 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TF) at doses of 25 or 50 micrograms/h
Number of subjects: 10
Study 1740198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 0
Study 1740198 — intervention group
Group type: COMPARATOR
Intervention: Intracervical insemination
Number of subjects: 0
Study 6325864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocardia rubra cell-wall skeleton (N-CWS) treatment
Number of subjects: 190
Study 6325864 — intervention group
Group type: COMPARATOR
Intervention: Control group (no N-CWS treatment)
Number of subjects: 190
Study 31500849 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning treatment (intermittent ischaemia and reperfusion applied to the arm through four cycles of 5‐min inflation and 5‐min deflation of an automated cuff device)
Number of subjects: 5401
Study 31500849 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (including a sham simulated remote ischaemic conditioning intervention at UK sites only)
Number of subjects: 5401
Study 28230557 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Dresden protocol (3 mW/cm for 30 min, dose 5.4 J/cm)
Number of subjects: 25
Study 28230557 — intervention group
Group type: COMPARATOR
Intervention: Accelerated protocol (30 mW/cm for 3 min 40 s, dose 6.6 J/cm)
Number of subjects: 25
Study 26984444 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic midurethral tape (MUT) procedure
Number of subjects: 100
Study 24434073 — intervention group
Group type: EXPERIMENTAL
Intervention: Coming Out Proud (COP)
Number of subjects: 100
Study 24434073 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control
Number of subjects: 100
Study 23700932 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldioxotetrahydropyrimidine sulfonisonicotinoyl hydrazide (MSH) at a daily dose of 800-1200 mg for 2-5 months
Number of subjects: 102
Study 23700932 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 102
Study 23700932 — intervention group
Group type: EXPERIMENTAL
Intervention: MSH on drug susceptible MBT
Number of subjects: 102
Study 23700932 — intervention group
Group type: EXPERIMENTAL
Intervention: MSH on drug resistant MBT (isoniazid MIC of 1 mcg/ml)
Number of subjects: 102
Study 23700932 — intervention group
Group type: EXPERIMENTAL
Intervention: MSH on isoniazid resistant MBT at 10 mcg/ml
Number of subjects: 102
Study 23700932 — intervention group
Group type: EXPERIMENTAL
Intervention: MSH
Number of subjects: 102
Study 20048237 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visitation program
Number of subjects: 643
Study 17394176 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Pain Management Program (BPM)
Number of subjects: 402